Indegene Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹275(60.84%)
Premium (ELP)
The Initial Public Offering of Indegene Limited's culminated in its successful listing on May 13, 2024 at the NSE, BSE trading platform. The company secured 4,07,46,891 Shares through this capital market exercise, with 1,68,14,159 Shares allocated to new capital formation and ₹1081.76 Cr to existing shareholder liquidity.
Investors participated within the price parameters of ₹430 to ₹452, with minimum investment requirements of 33 shares. The subscription period from May 06, 2024 to May 08, 2024 witnessed active investor engagement across categories.
Following the subscription closure, share allotment was processed on May 10, 2024. The subsequent listing established a public market for the company's shares, enabling price discovery and secondary market trading for investors.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in 1998, Indegene Limited is a leading digital solutions provider for the life sciences industry, helping companies with everything from drug development and clinical trials to regulatory submissions and sales & marketing. The company offers a wide range of services through its Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Enterprise Clinical Solutions, along with expert consultancy. Its subsidiary, DT Consulting, specializes in guiding life sciences firms through digital transformation to enhance customer experiences. Indegene has also been recognized for its workplace excellence, winning the Platinum Level award at the 2023 Healthy Workplace Conference and Awards. With a global team of 5,181 professionals and 65 active clients across India, North America, Europe, China, and beyond, Indegene continues to deliver innovative and impactful solutions for the life sciences sector.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Deep Healthcare Industry Expertise: A large portion of the team has healthcare backgrounds, enabling the company to understand sector-specific challenges and deliver tailored, effective solutions.
- Use of Advanced Digital Technologies: Employs AI, machine learning, and advanced analytics to automate processes, boost efficiency, and provide innovative, high-value solutions for clients.
- Strong Trust Among Leading Biopharma Companies: Delivers high-quality services that have helped build long-term relationships with major biopharma clients, including the top 20 by revenue, demonstrating reliability and adaptability to evolving industry needs.
- Influence of Industry Shifts: Operating within the life sciences sector makes the company sensitive to changing regulations, evolving healthcare policies, and rapid technological advancements. Slower industry growth or rising competition could impact its revenue and profitability.
- Complex Revenue Structures: The company’s business model and revenue streams may be difficult for investors to interpret, potentially causing hesitation and affecting its ability to raise capital for future expansion.
- BCP Topco VII Pte. Ltd
Indegene Limited
Link Intime India Private Limited